CSPM EDP Sciences logo
Access to submission and peer review system
Search
Menu
All issues Volume 6 (2025) Vis Cancer Med, 6 (2025) 4 References
Open Access
Issue
Vis Cancer Med
Volume 6, 2025
Article Number 4
Number of page(s) 6
DOI https://doi.org/10.1051/vcm/2025005
Published online 17 March 2025
  1. Cords L, de Souza N, Bodenmiller B. Classifying cancer-associated fibroblasts – the good, the bad, and the target. Cancer Cell. 2024;42(9):1480–1485. [CrossRef] [PubMed] [Google Scholar]
  2. Bedeschi M, Marino N, Cavassi E, Piccinini F, Tesei A. Cancer-associated fibroblast: role in prostate cancer progression to metastatic disease and therapeutic resistance. Cells. 2023;12(5):802. [CrossRef] [PubMed] [Google Scholar]
  3. Guo T, Xu J. Cancer-associated fibroblasts: a versatile mediator in tumor progression, metastasis, and targeted therapy. Cancer Metastasis Rev. 2024;43(3):1095–1116. [CrossRef] [PubMed] [Google Scholar]
  4. Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131. [Google Scholar]
  5. Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell. 2018;33(3):463–479.e10. [CrossRef] [PubMed] [Google Scholar]
  6. Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807–821. [CrossRef] [PubMed] [Google Scholar]
  7. Fan G, Yu B, Tang L, Zhu R, Chen J, Zhu Y, et al. TSPAN8(+) myofibroblastic cancer-associated fibroblasts promote chemoresistance in patients with breast cancer. Sci Transl Med. 2024;16(741):eadj5705. [Google Scholar]
  8. Chen B, Chan WN, Xie F, Mui CW, Liu X, Cheung AHK, et al. The molecular classification of cancer-associated fibroblasts on a pan-cancer single-cell transcriptional atlas. Clin Transl Med. 2023;13(12):e1516. [CrossRef] [PubMed] [Google Scholar]
  9. Croizer H, Mhaidly R, Kieffer Y, Gentric G, Djerroudi L, Leclere R, et al. Deciphering the spatial landscape and plasticity of immunosuppressive fibroblasts in breast cancer. Nat Commun. 2024;15(1):2806. [PubMed] [Google Scholar]
  10. Fang H, Dai W, Gu R, Zhang Y, Li J, Luo W, et al. myCAF-derived exosomal PWAR6 accelerates CRC liver metastasis via altering glutamine availability and NK cell function in the tumor microenvironment. J Hematol Oncol. 2024;17(1):126. [CrossRef] [PubMed] [Google Scholar]
  11. Huang H, Wang Z, Zhang Y, Pradhan RN, Ganguly D, Chandra R, et al. Mesothelial cell-derived antigen-presenting cancer-associated fibroblasts induce expansion of regulatory T cells in pancreatic cancer. Cancer Cell. 2022;40(6):656–673.e7. [CrossRef] [PubMed] [Google Scholar]
  12. Zhang T, Ren Y, Yang P, Wang J, Zhou H. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Cell Death Dis. 2022;13(10):897. [CrossRef] [PubMed] [Google Scholar]
  13. Galbo PM Jr., Zang X, Zheng D. Molecular features of cancer-associated fibroblast subtypes and their implication on cancer pathogenesis, prognosis, and immunotherapy resistance. Clin Cancer Res. 2021;27(9):2636–2647. [CrossRef] [PubMed] [Google Scholar]
  14. Hanley CJ, Noble F, Ward M, Bullock M, Drifka C, Mellone M, et al. A subset of myofibroblastic cancer-associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers. Oncotarget. 2016;7(5):6159–6174. [Google Scholar]
  15. Affo S, Yu LX, Schwabe RF. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol. 2017;12:153–186. [CrossRef] [PubMed] [Google Scholar]
  16. Mucciolo G, Araos Henríquez J, Jihad M, Pinto Teles S, Manansala JS, Li W, et al. EGFR-activated myofibroblasts promote metastasis of pancreatic cancer. Cancer Cell. 2024;42(1):101–118.e11. [CrossRef] [PubMed] [Google Scholar]
  17. Zhan Y, Sun D, Gao J, Gao Q, Lv Y, Du T, et al. Single-cell transcriptomics reveals intratumor heterogeneity and the potential roles of cancer stem cells and myCAFs in colorectal cancer liver metastasis and recurrence. Cancer Lett. 2025;612:217452. [CrossRef] [PubMed] [Google Scholar]
  18. Davidson G, Helleux A, Vano YA, Lindner V, Fattori A, Cerciat M, et al. Mesenchymal-like tumor cells and myofibroblastic cancer-associated fibroblasts are associated with progression and immunotherapy response of clear cell renal cell carcinoma. Cancer Res. 2023;83(17):2952–2969. [CrossRef] [PubMed] [Google Scholar]
  19. Chen M, Chen F, Gao Z, Li X, Hu L, Yang S, et al. CAFs and T cells interplay: The emergence of a new arena in cancer combat. Biomed Pharmacother. 2024;177:117045. [CrossRef] [PubMed] [Google Scholar]
  20. Lyu SI, Johannsen J, Simon AG, Knipper K, Wuerdemann N, Sharma SJ, et al. Co-expression patterns of cancer associated fibroblast markers reveal distinct subgroups related to patient survival in oropharyngeal squamous cell carcinoma. Front Cell Dev Biol. 2024;12:1337361. [CrossRef] [PubMed] [Google Scholar]
  21. Liu T, Liu C, Yan M, Zhang L, Zhang J, Xiao M, et al. Single cell profiling of primary and paired metastatic lymph node tumors in breast cancer patients. Nat Commun. 2022;13(1):6823. [PubMed] [Google Scholar]
  22. Santi A, Kugeratski FG, Zanivan S. Cancer associated fibroblasts: the architects of stroma remodeling. Proteomics. 2018;18(5–6)e1700167. [Google Scholar]
  23. Davidson S, Coles M, Thomas T, Kollias G, Ludewig B, Turley S, et al. Fibroblasts as immune regulators in infection, inflammation and cancer. Nat Rev Immunol. 2021;21(11):704–717. [Google Scholar]
  24. Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18(2):99–115. [CrossRef] [Google Scholar]
  25. Bonneaud TL, Lefebvre CC, Nocquet L, Basseville A, Roul J, Weber H, et al. Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties. Cell Death Dis. 2022;13(9):787. [CrossRef] [PubMed] [Google Scholar]
  26. Hanley CJ, Mellone M, Ford K, Thirdborough SM, Mellows T, Frampton SJ, et al. Targeting the myofibroblastic cancer-associated fibroblast phenotype through inhibition of NOX4. J Natl Cancer Inst. 2018;110(1):109–120. [CrossRef] [PubMed] [Google Scholar]
  27. Liu H, Shi Y, Qian F. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts. Adv Drug Deliv Rev. 2021; 172:37–51. [CrossRef] [PubMed] [Google Scholar]
  28. De Jesus-Acosta A, Sugar EA, O’Dwyer PJ, Ramanathan RK, Von Hoff DD, Rasheed Z, et al. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Br J Cancer. 2020;122(4):498–505. [CrossRef] [PubMed] [Google Scholar]
  29. Zhang Z, Chen L. Nanomaterials in cancer immunotherapy: targeting cancer-associated fibroblasts. Cancer Nanotechnol. 2025;16(1):2. [CrossRef] [Google Scholar]
  30. Mitsui E, Kikuchi S, Okura T, Tazawa H, Une Y, Nishiwaki N, et al. Novel treatment strategy targeting interleukin-6 induced by cancer associated fibroblasts for peritoneal metastasis of gastric cancer. Sci Rep. 2025;15(1):3267. [Google Scholar]
  31. Mellone M, Piotrowska K, Venturi G, James L, Bzura A, Lopez MA, et al. ATM regulates differentiation of myofibroblastic cancer-associated fibroblasts and can be targeted to overcome immunotherapy resistance. Cancer Res. 2022;82(24);4571–4585. [CrossRef] [PubMed] [Google Scholar]
  32. Kieffer Y, Hocine HR, Gentric G, Pelon F, Bernard C, Bourachot B, et al. Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer. Cancer Discov. 2020;10(9):1330–1351. [CrossRef] [PubMed] [Google Scholar]
  33. Rivas EI, Linares J, Zwick M, Gómez-Llonin A, Guiu M, Labernadie A, et al. Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors. Nat Commun. 2022;13(1):5310. [CrossRef] [PubMed] [Google Scholar]
  34. Dominguez CX, Müller S, Keerthivasan S, Koeppen H, Hung J, Gierke S, et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15(+) myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 2020;10(2);232–253. [CrossRef] [PubMed] [Google Scholar]
  35. Ou Z, Lin S, Qiu J, Ding W, Ren P, Chen D, et al. Single-nucleus RNA sequencing and spatial transcriptomics reveal the immunological microenvironment of cervical squamous cell carcinoma. Adv Sci (Weinh). 2022;9(29):e2203040. [CrossRef] [PubMed] [Google Scholar]
  36. Hu S, Lu H, Xie W, Wang D, Shan Z, Xing X, et al. TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma. J Clin Invest. 2022;132(19):e157649. [CrossRef] [PubMed] [Google Scholar]
  37. Jenkins L, Jungwirth U, Avgustinova A, Iravani M, Mills A, Haider S, et al. Cancer-associated fibroblasts suppress CD8+ T-cell infiltration and confer resistance to immune-checkpoint blockade. Cancer Res. 2022;82(16):2904–2917. [CrossRef] [PubMed] [Google Scholar]
  38. Tang PC, Chung JY, Xue VW, Xiao J, Meng XM, Huang XR, et al. Smad3 promotes cancer-associated fibroblasts generation via macrophage-myofibroblast transition. Adv Sci (Weinh). 2022;9(1):e2101235. [CrossRef] [PubMed] [Google Scholar]
  39. Lee KW, Yeo SY, Gong JR, Koo OJ, Sohn I, Lee WY, et al. PRRX1 is a master transcription factor of stromal fibroblasts for myofibroblastic lineage progression. Nat Commun. 2022;13(1):2793. [PubMed] [Google Scholar]
  40. Zhang H, Yue X, Chen Z, Liu C, Wu W, Zhang N, et al. Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials. Mol Cancer. 2023;22(1):159. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.